
The Gender Health Gap And Late Diagnosis Are Killing Women.




Reliance On Inaccurate Tests And Dated Technology Is The Root Cause Of Late Diagnosis.
ProSeek Bio is transforming biomarker-based diagnostics with our novel glycoproteomics platform.

Accurate
-
Science-based glycoform focus
-
Score derived from multiple markers

R&D Speed
-
Unified platform from research to clinical test
-
No lengthy reagent development

Cost Effective
-
Antibody-free
-
Multiple markers measured in one assay
-
Use existing clinical mass spcetrometer

Support
-
Full training and ongoing technical support
-
Partnering opportunity for new test R&D
ProSeek Bio is partnering with stakeholders to develop blood tests for unmet diagnostic needs in women's health.

ProSeek Bio has commercialisation rights for glycoform biomarkers for ovarian cancer discovered by founder A/Prof Michelle Hill through an agreement with QIMR Berghofer Medical Research Institute. International partners have been identified for assay development and clinical studies.

Endometriosis-associated ovarian cancer
Endometriosis is a painful condition affecting more than 10% of women. Women with endometriosis are four to ten times more likely to develop ovarian cancer compared to women without endometriosis. There is a gap and an opportunity for early ovarian cancer detection in women with endometriosis. ProSeek Bio is building international partnership to address this unmet need.

Autoimmune Conditions
Women are four times more likely to develop autoimmune conditions compared to men, and many suffered from medical gaslighting before eventual diagnosis. ProSeek Bio is seeking partners to change this narrative, by developing multi-glycoform biomarker blood tests for diagnosis of autoimmune conditions.

Effective Health Testing For All Women
Our Vision